| Devatis AG - Levodopa / Benserazid Devatis 62.5 mg (50 mg + 12.5 mg), Tabletten | | 68472 | | 01 | | Levodopa / Benserazid Devatis 62.5 mg (50 mg + 12.5 mg) | | Tabletten | | N04BA02 | | Levodopa und Decarboxylasehemmer | | 01.12.2021 | | |
| | Composition | | benserazidum 12.5 mg ut benserazidi hydrochloridum, levodopum 50 mg, natrii docusas, E 172 (rubrum), ethylcellulosum, silica colloidalis anhydrica, cellulosum microcristallinum, amylum pregelificatum, mannitolum, calcii hydrogenophosphas, crospovidonum, magnesii stearas, pro compresso corresp. natrium 0.00259 mg. | | Packungsbestandteile | | Comprimés | | | | | Principe actif | Concentr. |
|---|
| Benserazide | 12.5 mg | | Levodopa | 50 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Benserazide | 12.5 mg | | Levodopa | 50 mg |
| | | | Agents auxilliaires | | informations additionels |
|---|
| (Rubrum) | | | | Amylum Pregelificatum | | | | Calcium Hydrogenophosphate | | | | Cellulosum Microcristallinum | | | | Crospovidonum | | | | E 172 | | color. | | Ethylcellulosum | | | | Magnesii Stearas | | | | Mannitol | | | | Natrii Docusas | | | | Pro Compresso | | | | Silica Colloidalis Anhydrica | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 30 | 1.78 | 6.65 | B | | Oui | | 002 | 100 | 5.94 | 15.70 | B | LS | Oui |
|
|
